 |
|
Comparison of 2 Iron Doses in Infants Receiving Recombinant Human Erythropoietin Therapy
Shahid Nazir, MD;
Ricardo L. Peverini, MD;
Douglas D. Deming, MD;
Andrew O. Hopper, MD;
Nidia R. Vyhmeister, MD
Arch Pediatr Adolesc Med. 2002;156:540-544.
ABSTRACT
| |
Objective To compare iron sufficiency in premature infants receiving high-dose
recombinant human erythropoietin (r-HuEPO), 1200 IU/kg per week, supplemented
with 6 or 12 mg/kg per day of enteral iron.
Design We conducted a prospective, double-blind, controlled study of premature
infants receiving r-HuEPO therapy, randomly assigned to receive 2 different
doses of iron. Measurements of ferritin, iron, total iron-binding capacity,
reticulocyte count, hemoglobin level, and hematocrit were obtained at baseline,
4, and 6 weeks. Transferrin saturation was calculated; the number of blood
transfusions and the incidences of sepsis were recorded.
Setting This study was performed in the neonatal intensive care unit at Loma
Linda University Children's Hospital, Loma Linda, Calif.
Subjects Infants with a gestational age of 32 weeks or younger, older than 7
days, and receiving r-HuEPO therapy from March 1, 1997, to June 30, 1998,
were eligible for the study. Infants were randomly assigned to receive 6 mg/kg
per day or 12 mg/kg per day of enteral iron during a course of r-HuEPO therapy
for 4 to 6 weeks.
Results Sixty-four infants were enrolled in the study. Twelve infants did not
complete the study; 52 completed 4 weeks and 41 completed 6 weeks of the study.
While ferritin levels and transferrin saturation decreased in both groups
over the study period, there were no differences between the 2 study groups.
Conclusions Infants receiving high-dose r-HuEPO therapy (1200 IU/kg per week) decrease
their ferritin levels (measure of iron stores) even when receiving high enteral
iron supplementation. Given that the ferritin levels were similar between
the 2 groups, we speculate that the additional iron either was not absorbed
or was not stored.
INTRODUCTION
INADEQUATE ERYTHROPOIETIN levels are a major factor in the cause of
anemia of prematurity.1-7
Recombinant human erythropoietin (r-HuEPO) is used frequently to treat anemia
of prematurity and has been shown to increase the reticulocyte count, hemoglobin
level, and hematocrit and to decrease the number and volume of erythrocyte
transfusions in premature infants.8-13
Different doses of r-HuEPO have been evaluated by various clinical trials.
The combination of r-HuEPO and iron supplementation has been shown to enhance
erythropoiesis in premature infants compared with giving r-HuEPO alone.14 The erythropoietic response is dose-dependent12 and a significant reticulocyte response with increased
hematocrit has been obtained using high-dose r-HuEPO therapy (1200 IU/kg per
week).15 We routinely use this high-dose of
r-HuEPO in our neonatal intensive care unit to maximize erythropoiesis.
Increased erythropoiesis depletes the body iron stores.13, 16
Erythropoietin use in animal models decreases plasma, hepatic, cardiac, and
skeletal muscle iron stores.17 A similar decrease
in iron content has been found in the liver, heart, and brain of infants having
augmented erythropoeisis and who were born to mothers with diabetes mellitus.18 Use of r-HuEPO therapy in humans causes a significant
fall in the serum ferritin level, a major indicator of iron stores.13, 16, 19 Most clinical studies
in newborn infants use serum ferritin to assess iron stores because it is
impractical to perform invasive procedures such as liver or bone marrow biopsies.20-24
Serum iron level, transferrin saturation, and total iron binding capacity
(TIBC), less sensitive indicators of iron sufficiency, are also affected and
inversely related to the r-HuEPO dose.11
The ideal amount of iron supplementation while receiving r-HuEPO is
unknown. In an early study, Shannon10 administered
6 mg/kg per day of iron enterally during r-HuEPO therapy (500 IU/kg per week).
Other studies have also used 6 mg/kg per day of enteral iron during r-HuEPO
therapy.8-9,25-27
Based on the findings from these studies, it has been the practice in our
neonatal intensive care unit to administer 6 mg/kg per day of enteral iron
for infants receiving r-HuEPO therapy. Considering the potential of r-HuEPO
therapy to cause iron deficiency and recognizing that we use a high-dose of
r-HuEPO, we wished to determine a sufficient but not excessive iron supplementation
dosage.15 Therefore, we designed a study to
evaluate iron sufficiency in premature infants receiving high-dose r-HuEPO
supplementation at a dosage of 6 mg/kg per day of enteral iron (our standard
dose) vs 12 mg/kg per day of enteral iron. We hypothesized that using a higher
dose of enteral iron supplementation would prevent functional iron deficiency
(iron being unavailable for incorporation into the erythrocytes) and enhance
erythropoiesis in premature infants treated with r-HuEPO. We selected the
higher dose of iron expecting to provide sufficient iron for the high dose
of r-HuEPO used, but not so high a dose as to risk the toxic effects of iron
or gastrointestinal intolerance.
SUBJECTS AND METHODS
To determine iron sufficiency for premature infants receiving erythropoietin
therapy, we designed a prospective, randomized study to evaluate the effects
of 2 different doses of enteral iron supplementation in premature infants
who were receiving 1200 IU/kg per week of r-HuEPO (the standard dose used
in our unit for such infants). Recombinant human erythropoietin (Epoetin Alfa;
Amgen Inc, Thousand Oaks, Calif) was administered either intravenously, if
access was available, or subcutaneously. The randomization code was developed
using a computer random number generator to select random permuted blocks.
The block lengths of 4 and 6 were randomly varied. The hospital pharmacist
assigned infants to receive enteral iron as ferrous sulfate (Mead Johnson
Pharmaceuticals, Indianapolis, Ind) at 6 mg/kg per day or 12 mg/kg per day.
The enteral iron supplements were prepared in the pharmacy and placed in syringes
with the actual dose concealed from the caregivers and investigators.
We used the levels of serum ferritin and serum iron, as well as the
TIBC to determine the status of iron stores. Transferrin saturation was calculated
for each infant at each study time point. Reticulocyte count, hemoglobin level,
hematocrit, incidence of sepsis, and the number and volume of erythrocyte
transfusions were recorded as secondary variables. These tests were performed
at baseline and were repeated at 4 and 6 weeks. This study was approved by
the institutional review board of Loma Linda University Children's Hospital,
Loma Linda, Calif. Parental consent was obtained.
SUBJECT SELECTION
All infants admitted to the neonatal intensive care unit at Loma Linda
University Children's Hospital with a gestational age of 32 weeks or younger,
older than 7 days of life, and receiving r-HuEPO therapy were eligible to
be enrolled in this study. Infants were excluded from the study if, at the
time of enrollment, they had a contraindication to receive enteral iron supplementation
(eg, feeding intolerance). Infants were removed from the study if they developed
gastrointestinal symptoms precluding enteral intake for longer than 10 days.
PROTOCOL
Infants were randomized to receive 6 or 12 mg/kg per day of enteral
iron, starting when they were tolerating a minimum of 50 mL/kg per day of
enteral feedings. Iron supplementation was begun within 10 days of the initiation
of r-HuEPO therapy. Infants were studied at baseline and at 4 weeks. Additional
measurements were obtained for infants who remained hospitalized at 6 weeks.
The caregivers were masked to the iron dosage and provided routine neonatal
care.
The total quantity of blood drawn and transfused during the study was
recorded and compared between the 2 groups. Clinicians caring for infants
ordered erythrocyte transfusions without consulting the investigators. Infants
were transfused based on written guidelines developed for our neonatal intensive
care unit based on the criteria of Shannon et al.9
LABORATORY ANALYSIS
Ferritin levels were measured using microparticle enzyme immunoassay
technology (Abbot AxSYM; Abbott Laboratories, Abbott Park, Ill). Iron and
TIBC levels were determined using a timed endpoint method (Beckman Synchron
CX4CE; Beckman Coulter Inc, Fullerton, Calif). Reticulocyte count was performed
using a flow cytometry technique argon laser (avamine-o-dye) fluorescence
(Sysmex-R-3000; Roche Diagnostics). Hemoglobin and hematocrit values were
measured using a modification of the manual cyanmethemoglobin method (Advia
120; Bayer Diagnostics, Tarrytown, NY).
STATISTICAL ANALYSES
A sample size of 27 infants in each group was calculated to detect a
40% difference in the plasma ferritin level with an  level of .05 and
80% power. This sample size would be insufficient to detect smaller differences.
Statistics were calculated using SPSS for Windows, Version 10 (SPSS Inc, Chicago,
Ill). Demographic statistics were calculated to define the infant population.  2 Test was used to analyze the incidence of sepsis and to compare the
numbers of transfusions. Mann-Whitney test was used to compare differences
for age at the start of study and blood volume both withdrawn and transfused.
Two-way analysis of variance for repeated measures was used to compare the
values of serum ferritin, serum iron, TIBC, reticulocyte count, and hematocrit
over the course of the study between the 2 iron supplementation groups.
RESULTS
Sixty-four infants of 32 weeks' gestational age or younger were enrolled
between March 1, 1997, and June 30, 1998. Infants were randomly assigned to
receive either 6 mg/kg per day or 12 mg/kg per day of iron supplementation.
Twelve infants were excluded from the study before the fourth week (3 from
the 6 mg/kg per day iron group and 9 from the 12 mg/kg per day iron group).
One infant from the 6 mg/kg per day iron group was excluded due to necrotizing
enterocolitis. Two infants (1 from each iron dosage group) were excluded due
to feeding intolerance. Nine of the 12 infants (8 from the 12 mg/kg per day
iron group and 1 from the 6 mg/kg per day iron group) exited the study owing
to hospital discharge to home prior to 4 weeks. These 9 infants had similar
baseline hematocrit values, discharge weights, and gestational ages when compared
with the infants discharged after 6 weeks. Six of those 9 infants had an increase
in hematocrit from baseline prior to their discharge while 3 had a decrease
in hematocrit. Thus, 52 infants completed 4 weeks of study, 29 in the 6 mg/kg
per day iron group and 23 in the 12 mg/kg per day iron group. Forty-one of
the 52 infants completed 6 weeks of the study, 23 in the 6 mg/kg per day iron
group and 18 in the 12 mg/kg per day iron group. There were no significant
differences between the 2 iron supplementation groups at enrollment for birth
weight or gestational age. There were no differences at the start of the study
for age, weight, or hematocrit. There was no difference in weight at the end
of the study (Table 1).
|
|
|
|
Demographic Values and Characteristics of the Study Population*
|
|
|
Serum ferritin levels decreased significantly from baseline during the
r-HuEPO course in both the 6 mg/kg per day and the 12 mg/kg per day iron groups
(P<.001) at 4 and 6 weeks. There was no statistical
difference between the 2 iron supplementation groups (Figure 1). The serum iron level and TIBC did not show any significant
difference either in time sequence or between groups during the r-HuEPO course.
Transferrin saturation decreased significantly over time (P<.007), but the difference between the 2 iron supplementation groups
was not statistically significant (Figure
1). Additionally, there was no statistical difference in volume
of blood drawn or transfused between the 2 iron supplementation groups during
the study (Table 1).
|
|
|
|
Figure 1. Ferritin levels (A), serum iron
levels (B), and transferrin saturation (C) at baseline, 4 weeks, and 6 weeks
of the study for the 6 mg/kg per day and 12 mg/kg per day iron supplementation
groups. r-HuEPO indicates recombinant human erythropioetin.
|
|
|
Infants in both groups had similar hematocrits at baseline and maintained
steady values throughout the study. There was no difference in hematocrits
between the groups at 4 weeks and 6 weeks of r-HuEPO therapy. The total reticulocyte
count for both iron groups was significantly higher at 4 and 6 weeks of r-HuEPO
therapy compared with baseline for each group (P<.05),
even though there was no significant difference between the 2 iron supplementation
groups (Figure 2).
|
|
|
|
Figure 2. Hematocrit (A) and reticulocyte
count (B) at baseline, 4 weeks, and 6 weeks of study for the 6 mg/kg per day
and 12 mg/kg per day iron groups. r-HuEPO indicates recombinant human erythropioetin.
|
|
|
Fourteen infants had either clinical or culture-proven sepsis during
the study (11 in the 6 mg/kg per day iron group and 3 in the 12 mg/kg per
day iron group). Clinical sepsis was defined as an infant developing clinical
findings (temperature instability, lethargy, or poor perfusion) and laboratory
value changes (leukocytosis, bandemia, neutropenia, or metabolic acidosis)
that responded to antibiotic therapy. Eighteen episodes of sepsis were identified
in the 14 infants. Four sepsis episodes were culture proven (3 in the 6 mg/kg
per day iron group and 1 in the 12 mg/kg per day iron group) while 14 episodes
were clinically diagnosed (11 in the 6 mg/kg per day iron group and 3 in the
12 mg/kg per day iron group). We did not see an increased incidence of sepsis
episodes in the higher iron supplementation group.
COMMENT
We have shown that infants receiving 1200 IU/kg per week of r-HuEPO
therapy decrease their iron stores while receiving 6 mg/kg per day or 12 mg/kg
per day dose of supplemental enteral iron. There was no difference between
the groups in the decrease of ferritin levels despite using a larger iron
dose. No single laboratory test for evaluation of iron stores provides a complete
picture. We compared the serum ferritin and serum iron level as well as the
TIBC. Ferritin is considered the most specific indicator available to assess
iron stores. Since we were using the high amount of iron, we wanted to be
sure that this would not produce excess body iron. Our study shows that 12
mg/kg per day enteral iron did not produce gastrointestinal intolerance, and
did not cause toxic levels of stored iron (high serum ferritin levels) or
increase the incidence of sepsis.
In healthy infants, the serum ferritin level rises sharply in the first
month of life when iron shifts from erythrocyte to the storage compartment9, 27-32
It then falls over the next 3 months as iron is used to meet the needs of
the rapidly expanding erythrocyte mass. This may not be true for the premature
infant in whom erythropoiesis may not start until later. Our study showed
a marked variation in serum ferritin levels in both iron groups over the study,
particularly at baseline. This variation in ferritin levels compounds the
difficulty in interpreting whether an infant's iron stores are depleted and
points out the need for studies that will establish normal values for ferritin
in premature infants of different gestational age at different postconceptional
age.
The decrease in ferritin levels and transferrin saturation in both the
6 mg/kg per day and 12 mg/kg per day iron groups may reflect iron use by augmented
erythropoiesis.32 However, we did not demonstrate
a proportional increase in hematocrit in the 12 mg/kg per day iron group.
Possible explanations for this include increased use of iron by other body
tissues (eg, brain) or decreased absorption or retention of iron.20-24
It has been suggested either that very low-birth-weight infants may poorly
regulate iron absorption or that the level of serum ferritin is a poor marker
of iron needs.33-34
It is possible that a decrease in enteral iron absorption could explain
the lack of increase in the level of serum ferritin that we observed. Substances
like phosphates and calcium may decrease iron absorption by forming insoluble
complexes. Premature infants received high amounts of phosphorus and calcium
in their premature formulas or were supplemented with calcium and phosphorus
if receiving human milk. Additionally, we speculate that if more iron was
used in the production of hemoglobin or that if iron was used for incorporation
into other tissues, then the iron stores would not show an increase.
Our study used a higher dose of r-HuEPO (1200 IU/kg per week) than most
other studies. This dose may have exacerbated the observed decrease in iron
stores, despite iron supplementation as high as 12 mg/kg per day. An even
higher dose of iron might improve the effectiveness of our higher dose r-HuEPO
therapy. In a recent study, the effect on erythropoiesis was compared in very
low-birth-weight infants with r-HuEPO treatment and receiving oral or parenteral
iron. The infants receiving parenteral iron had significantly higher serum
ferritin levels, but the hemoglobin and hematocrit values were not different
between the 2 groups.34 This lack of difference
in hemoglobin and hematocrit suggests that despite a high serum ferritin level,
the iron was unavailable for incorporation into the erythrocytes or that there
was functional iron deficiency.
Parenteral iron use (but probably not enteral iron) carries a risk of
iron overload.35 The parenteral route bypasses
the homeostatic control otherwise exerted through the gastrointestinal mucosa.
Both iron dextran and iron sucrose, the available Food and Drug Administration–approved
preparations of parenteral iron, form iron polymers that are absorbed intact
into the lymphatic system. This may lead to serum iron levels that exceed
the TIBC for several hours after the injection. This polymeric iron is not
bound to transferrin and may encourage bacterial growth. In determining the
appropriate dosage of supplemental iron, either high oral or parenteral, oxidative
damage should be assessed. Free radical damage from iron excess may be more
important to avoid than the intake of enough iron to produce erythropoiesis.
Parenteral iron supplementation needs to be studied to prove its safety in
premature infants before it is widely used.
We did not see an increase in sepsis in the 12 mg/kg oral iron group.
Since there have been concerns that high iron supplementation may predispose
to sepsis, this finding may be reassuring concerning the use of oral iron
and the risk of infection.
We have shown that premature infants receiving 1200 IU/kg per week of
r-HuEPO therapy decrease their iron stores while receiving 6 or 12 mg/kg per
day of enteral iron supplementation. Considering the long-lasting and at times
irreparable effects of iron deficiency during infancy,36-40
iron supplementation needs to be sufficient to meet the iron demands of erythropoiesis
as well as the needs of other tissues (eg, brain). The large variation in
the level of serum ferritin and other measures of iron sufficiency make it
difficult to determine the adequacy of iron stores. There are no sequential
postnatal normal values of serum ferritin by gestational age. The optimal
amount of iron, type of iron preparation, and route of administration for
premature infants with augmented erythropoiesis remain to be determined.
| What This Paper Adds
Adequate iron supply is essential for erythropoiesis in premature infants
receiving high doses of r-HuEPO therapy. We hypothesized that using higher
doses of r-HuEPO, which has been demonstrated to promote erythropoiesis, would
require increased iron supplementation. We wanted to determine the dose of
iron that would be sufficient to achieve maximal erythropoiesis without producing
toxic effects. Therefore, we designed a prospective, randomized study to evaluate
the effects of 2 different doses of enteral iron supplementation in premature
infants who were receiving 1200 IU/kg per week of r-HuEPO therapy.
This study shows that following 4 and 6 weeks of r-HuEPO therapy with
either 6 mg/kg per day or 12 mg/kg per day of oral iron supplementation, premature
infants showed similar ferritin levels, serum iron levels, transferrin saturations,
and hematocrits. Given that the ferritin levels were equal in the infants
given twice as much iron as the lower-dose group, the additional iron was
either poorly absorbed, not stored, or used by other tissues. We were unable
to show better erythropoiesis in the infants with the high enteral iron dose.
The optimal amount of iron, type of iron preparation, and route of administration
for premature infants with augmented erythropoiesis remain to be determined.
|
|
AUTHOR INFORMATION
Accepted for publication February 21, 2002.
This study was supported by the Pediatric Research Fund, School of Medicine,
Loma Linda University.
Dr Nazir was a neonatology fellow.
Corresponding author and reprints: Nidia R. Vyhmeister, MD, Department
of Pediatrics, Coleman Pavilion, Loma Linda, CA 92354 (e-mail: nvyhmeister{at}ahs.llumc.edu).
From the Department of Pediatrics, Loma Linda University School of
Medicine (Drs Peverini, Deming, Hopper, and Vyhmeister), Loma Linda, Calif.
Dr Nazir is in private practice in Colton, Calif.
REFERENCES
| |
1. Stockman III JA, Garcia JF, Oski FA. The anemia of prematurity: factors governing the erythropoietin response. N Engl J Med. 1977;296:647-650.
ABSTRACT
2. Brown MS, Phibbs RH, Garcia JF, Dallman PR. Postnatal changes in erythropoietin levels in untransfused premature
infants. J Pediatr. 1983;103:612-617.
FULL TEXT
|
ISI
| PUBMED
3. Brown MS, Garcia JF, Phibbs RH, Dallman PR. Decreased response of plasma immunoreactive erythropoietin to "available
oxygen" in anemia of prematurity. J Pediatr. 1984;105:793-798.
FULL TEXT
|
ISI
| PUBMED
4. Shannon KM, Naylor GS, Torkildson JC, et al. Circulating erythroid progenitors in the anemia of prematurity. N Engl J Med. 1987;317:728-733.
ABSTRACT
5. Rhondeau SM, Christensen RD, Ross MP, Rothstein G, Simmons MA. Responsiveness to recombinant human erythropoietin of marrow erythroid
progenitors from infants with the "anemia of prematurity." J Pediatr. 1988;112:935-940.
FULL TEXT
|
ISI
| PUBMED
6. Soubasi V, Kremenopoulos G, Diamanti E, Tsantali C, Sarafidis K, Tsakiris D. Follow-up of very low birth weight infants after erythropoietin treatment
to prevent anemia of prematurity. J Pediatr. 1995;127:291-297.
FULL TEXT
|
ISI
| PUBMED
7. Strauss RG. Recombinant erythropoietin for the anemia of prematurity: still a promise,
not a panacea. J Pediatr. 1997;131:653-655.
ISI
| PUBMED
8. Shannon KM, Mentzer WC, Abels RI, et al. Enhancement of erythropoiesis by recombinant human erythropoietin in
low birth weight infants: a pilot study. J Pediatr. 1992;120:586-592.
FULL TEXT
|
ISI
| PUBMED
9. Shannon KM, Keith III JF, Mentzer WC, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces
erythrocyte transfusions in very low-birth-weight preterm infants. Pediatrics. 1995;95:1-8.
FREE FULL TEXT
10. Shannon K. Recombinant human erythropoietin in neonatal anemia. Clin Perinatol. 1995;22:627-640.
ISI
| PUBMED
11. Messer J, Haddad J, Donato L, Astruc D, Matis J. Early treatment of premature infants with recombinant human erythropoietin. Pediatrics. 1993;92:519-523.
FREE FULL TEXT
12. Halperin DS, Wacker P, Lacourt G, et al. Effects of recombinant human erythropoietin in infants with the anemia
of prematurity: a pilot study. J Pediatr. 1990;116:779-786.
FULL TEXT
|
ISI
| PUBMED
13. Maier RF, Obladen M, Scigalla P, et al for the European Multicentre Erythropoietin Study Group. The effect of Epoetin Beta (recombinant human erythropoietin) on the
need for transfusion in very-low-birth-weight infants. N Engl J Med. 1994;330:1173-1178.
FREE FULL TEXT
14. Carnielli VP, Da Riol R, Montini G. Iron supplementation enhances response to high doses of recombinant
human erythropoietin in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1998;79:F44-F48.
15. Carnielli V, Montini G, Da Riol R, Dall'Amico R, Cantarutti F. Effect of high doses of human recombinant erythropoietin on the need
for blood transfusions in preterm infants. J Pediatr. 1992;121:98-102.
FULL TEXT
|
ISI
| PUBMED
16. Meyer MP, Haworth C, Meyer JH, Commerford A. A comparison of oral and intravenous iron supplementation in preterm
infants receiving recombinant erythropoietin. J Pediatr. 1996;129:258-263.
FULL TEXT
|
ISI
| PUBMED
17. Georgieff MK, Schmidt RL, Mills MM, Radmer WJ, Widness JA. Fetal iron and cytochrome c status after intrauterine
hypoxemia and erythropoietin administration. Am J Physiol. 1992;262:R485-R491.
18. Petry CD, Eaton MA, Wobken JD, Mills MM, Johnson DE, Georgieff MK. Iron deficiency of liver, heart, and brain in newborn infants of diabetic
mothers. J Pediatr. 1992;121:109-114.
FULL TEXT
|
ISI
| PUBMED
19. Meyer MP, Meyer JH, Commerford A, et al. Recombinant human erythropoietin in the treatment of the anemia of
prematurity. Pediatrics. 1994;93:918-923.
FREE FULL TEXT
20. Aggett PJ. Trace elements of the micropremie. Clin Perinatol. 2000;27:119-129, vi.
FULL TEXT
|
ISI
| PUBMED
21. Abbas A, Snijders RJ, Sadullah S, Nicolaides KH. Fetal blood ferritin and cobalamin in normal pregnancy. Fetal Diagn Ther. 1994;9:14-18.
ISI
| PUBMED
22. Ben Hariz M, Goulet O, De Potter S, et al. Iron overload in children receiving prolonged parenteral nutrition. J Pediatr. 1993;123:238-241.
FULL TEXT
|
ISI
| PUBMED
23. Brown MS. Effect of transfusion and phlebotomy on serum ferritin levels in low
birth weight infants. J Perinatol. 1996;16:39-42.
PUBMED
24. Saarinen UM, Siimes MA, Dallman PR. Iron absorption in infants: high bioavailability of breast milk iron
as indicated by the extrinsic tag method of iron absorption and by the concentration
of serum ferritin. J Pediatr. 1977;91:36-39.
FULL TEXT
|
ISI
| PUBMED
25. Ohls RK, Osborne KA, Christensen RD. Efficacy and cost analysis of treating very low-birth-weight infants
with erythropoietin during their first two weeks of life: a randomized, placebo-controlled
trial. J Pediatr. 1995;126:421-426.
FULL TEXT
|
ISI
| PUBMED
26. Kling PJ, Widness JA, Guillery EN, Veng-Pedersen P, Peters C, DeAlarcon PA. Pharmacokinetics and pharmacodynamics of erythropoietin during therapy
in an infant with renal failure. J Pediatr. 1992;121:822-825.
FULL TEXT
|
ISI
| PUBMED
27. Brown MS, Shapiro H. Effect of protein intake on erythropoiesis during erythropoietin treatment
of anemia of prematurity. J Pediatr. 1996;128:512-517.
FULL TEXT
|
ISI
| PUBMED
28. Haga P. Plasma ferritin concentrations in preterm infants in cord blood and
during the early anaemia of prematurity. Acta Paediatr Scand. 1980;69:637-641.
ISI
| PUBMED
29. Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm
infants weighing 750 grams or less: a randomized, double-blind, placebo controlled
study. J Pediatr. 1997;131:661-665.
FULL TEXT
|
ISI
| PUBMED
30. Siimes MA, Addiego JE Jr, Dallman PR. Ferritin in serum: diagnosis of iron deficiency and iron overload in
infants and children. Blood. 1974;43:581-590.
FREE FULL TEXT
31. Diagne I, Archambeaud MP, Diallo D, d'Oiron R, Yvart J, Tchernia G. Erythrocyte indices and iron stores in cord blood. Arch Pediatr. 1995;2:208-214.
FULL TEXT
|
ISI
| PUBMED
32. Olivares M, Llaguno S, Marin V, Hertrampf E, Mena P, Milad M. Iron status in low-birth-weight infants, small and appropriate for
gestational age: a follow-up study. Acta Paediatr. 1992;81:824-828.
ISI
| PUBMED
33. Ehrenkranz RA, Gettner PA, Nelli CM, et al. Iron absorption and incorporation into red blood cells by very low
birth weight infants: studies with the stable isotope 58Fe. J Pediatr Gastroenterol Nutr. 1992;15:270-278.
ISI
| PUBMED
34. Pollak A, Hayde M, Hayn M, et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated
premature infants. Pediatrics. 2001;107:78-85.
FREE FULL TEXT
35. Zlotkin SH, Blosmanis E. Iron overload in patients on TPN. Pediatr Res. 1991;29:4:117A.
36. Dallman PR, Siimes MA, Manies EC. Brain iron: persistent deficiency following short-term iron deprivation
in the young rat. Br J Haematol. 1975;31:209-215.
ISI
| PUBMED
37. Dallman PR. Biochemical basis for the manifestations of iron deficiency. Annu Rev Nutr. 1986;6:13-40.
FULL TEXT
|
ISI
| PUBMED
38. Walter T, De Andraca I, Chadud P, Perales CG. Iron deficiency anemia: adverse effects on infant psychomotor development. Pediatrics. 1989;84:7-17.
FREE FULL TEXT
39. Lozoff B, Jimenez E, Wolf AW. Long-term developmental outcome of infants with iron deficiency. N Engl J Med. 1991;325:687-694.
ABSTRACT
40. Lozoff B, Wolf AW, Jimenez E. Iron-deficiency anemia and infant development: effects of extended
oral iron therapy. J Pediatr. 1996;129:382-389.
FULL TEXT
|
ISI
| PUBMED
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Is supplementary iron useful when preterm infants are treated with erythropoietin?
Ridley et al.
Arch. Dis. Child. 2006;91:1036-1038.
FULL TEXT
|
